A new clinical trial by Microbio Co. has found that consuming the company’s MS-20 gut health ingredient alongside ulcerative colitis medication gives patients greater symptom relief. The postbiotic is produced through symbiotic fermentation by multi-strain probiotics and was initially approved to alleviate chemotherapy side effects. When used as an additional therapy next to Keytruda, an ulcerative colitis medication, 83.3% of patients achieved clinical remission at week 12, compared to 35.7% in the placebo group.
